Interventional Cardiology · Trial Analysis

CTO PCI Beyond Placebo: What ORBITA-CTO Means for Angina Relief and the Devices Behind It

A blinded, sham-controlled trial finally answers whether opening a chronic total occlusion truly relieves angina — and what it means for operators, patients, and the device makers who supply the CTO toolkit.

Case Vignette

A 64-year-old man with a right coronary artery chronic total occlusion continues to report daily exertional chest pressure despite three antianginal agents.

His stress imaging confirms inferior ischemia with preserved viability, and his J-CTO complexity score is 2, suggesting a technically favorable target.

He asks the question every interventionalist has heard for two decades: will opening this artery actually make him feel better, or am I just going to feel better because I believe it will work.

The ORBITA-CTO trial was designed precisely to answer that question, and this article walks through what it found and what it means for practice.

Why a Sham-Controlled CTO Trial Was Overdue

Chronic total occlusion lesions are found in roughly one in five patients undergoing coronary angiography, yet only a minority are ever revascularized.

Historically, the case for CTO PCI rested on observational registries and open-label trials, all of which are vulnerable to placebo and expectancy effects that famously distorted our understanding of PCI for stable angina in the original ORBITA trial.

That uncertainty is baked into current guidance, where the 2021 ACC/AHA/SCAI revascularization guideline assigns CTO PCI for refractory angina only a weak, Class 2b recommendation.

Prior CTO-specific data were also mixed, with the open-label EURO-CTO trial and the OPEN-CTO registry showing symptom benefit while the randomized DECISION-CTO trial did not, a discrepancy widely attributed to a roughly 20% treatment crossover rate.

ORBITA-CTO was built to remove that ambiguity by comparing real CTO PCI against a meticulously blinded sham procedure.

Trial Design: Engineering Away the Placebo Effect

Investigators enrolled patients with a single-vessel CTO, objective ischemia and viability in that territory, no significant bystander disease, and a J-CTO score of 3 or less to keep technical failure rates low.

Before randomization, antianginal therapy was optimized and then completely withdrawn, and patients recorded their symptoms daily on the ORBITA smartphone app for a full week to establish a true symptomatic baseline.

Blinding was maintained with unusual rigor: bilateral arterial access and dual angiography were performed in every patient, clocks and phones were removed from the cath lab and wards, patients wore headphones for auditory isolation, and the sham group underwent a full hour of simulated PCI motions and equipment calls.

Two 1-minute infusions of intracoronary adenosine were even given in the placebo arm to reproduce the transient chest discomfort patients might expect from balloon inflation.

Antianginal medications could be reintroduced at the patient's discretion during the 24-week blinded follow-up, and the primary endpoint was a composite ordinal angina symptom score.

Design Element	Detail
Structure	Investigator-initiated, multicenter, double-blind, 1:1 randomized, placebo-procedure controlled
Population	50 patients (25 PCI, 25 sham); median age 64; 74% men
Lesion criteria	Single-vessel CTO, J-CTO score ≤3, ischemia + viability, no significant bystander disease
Operators	Two experienced CTO specialists, each performing ≥200 CTO cases annually
Follow-up	24 weeks, blinded
Primary endpoint	Angina symptom score (daily app-reported episodes + antianginal use + overrides)

The Results: A Real, Measurable Signal

Successful wire crossing was achieved in 96% of the PCI arm, confirming that the operators and lesion selection were appropriately matched to the trial's ambitions.

CTO PCI significantly improved the angina symptom score relative to the sham procedure, with an odds ratio of 4.38 and a 99.6% posterior probability of benefit.

Patients treated with PCI accumulated roughly 30 additional angina-free days over the 6-month follow-up compared with the placebo group.

Secondary Seattle Angina Questionnaire domains also favored PCI, including a mean 13.5-point improvement in physical limitation and an 18.2-point improvement in disease-specific quality of life.

Critically, the blinded, physician-assessed Canadian Cardiovascular Society angina class improved significantly more in the PCI arm even though the assessing physicians did not know which procedure the patient had received.

There was no significant difference in antianginal medication use between arms at 6 months, meaning the symptomatic benefit occurred despite, not because of, differential drug therapy.

Figure 1. Key ORBITA-CTO effect sizes. Odds ratio panel shows point estimate and 95% credible interval on a log-scaled reference line; bar lengths for SAQ domains are proportional to reported mean differences. Data synthesized from the trial report and ACC.26 congress coverage.

The Central Illustration

Central Illustration. Trial design, population characteristics, and primary results of ORBITA-CTO, reproduced from the original publication for physician reference.

How This Fits the Broader CTO Evidence Base

The original ORBITA trial in 2017 first demonstrated that non-CTO PCI produced no significant symptomatic advantage over a sham procedure, forcing the field to reckon with the size of the placebo response to invasive treatment.

The follow-up ORBITA-2 trial subsequently showed that PCI does produce genuine symptom benefit in stable angina once medical therapy is stripped away before randomization, a methodological template that ORBITA-CTO borrowed directly.

Applying that same rigor to CTO lesions was the logical next step, since CTO PCI is technically harder, carries higher procedural risk, and had never been tested against a true placebo.

According to the accompanying SCAI congress summary, ORBITA-CTO now represents the first blinded, placebo-controlled trial specifically designed to isolate the true symptomatic effect of CTO recanalization.

A detailed PCRonline congress analysis further reported that blinding fidelity was excellent in both arms, with Bang's blinding index well within the prespecified neutral range, lending additional credibility to the primary result.

An editorial by Dr. Ziad Ali frames the trial as clarifying rather than final, arguing that it confirms CTO PCI can work while leaving open exactly when and for whom it works best.

Study	Design	Symptom Benefit Shown?
EURO-CTO (2018)	Open-label RCT vs. optimal medical therapy	Yes
OPEN-CTO Registry	Prospective observational registry	Yes
DECISION-CTO (2019)	Open-label RCT, high crossover (~20%)	No sustained benefit
ORBITA (2017)	Sham-controlled, non-CTO stable angina	No significant benefit
ORBITA-2 (2023)	Sham-controlled, medical therapy stripped pre-randomization	Yes
ORBITA-CTO (2026)	Sham-controlled, single-vessel CTO, J-CTO ≤3	Yes, beyond placebo

Clinical Takeaways for the Cath Lab

For carefully selected patients — single-vessel disease, documented ischemia and viability, and manageable lesion complexity — ORBITA-CTO provides the first placebo-adjusted evidence that recanalization meaningfully reduces angina burden.

The magnitude of benefit is real but moderate, not dramatic, and roughly 30% of successful cases still required a retrograde approach, underscoring that these remain technically demanding procedures best reserved for experienced CTO operators.

The trial does not address multivessel disease, refractory angina despite maximal therapy in more complex anatomy, or J-CTO scores of 4 to 5, so extrapolation beyond the enrolled population should be cautious.

Practically, this data may support upgrading the current Class 2b guideline recommendation in future revisions, though that determination rests with the writing committees rather than a single 50-patient trial.

Shared decision-making remains essential, since even successful PCI did not eliminate angina or antianginal medication use in every patient.

Bottom Line

ORBITA-CTO is the first sham-controlled trial to isolate a genuine, placebo-adjusted symptomatic benefit from CTO PCI, supporting its selective use in carefully chosen patients treated by high-volume CTO operators, while leaving broader generalizability and guideline reclassification as open questions.

---

Physician-Investor Perspective: The CTO Toolkit and Its Makers

CTO recanalization depends on a specialized ecosystem of guidewires, microcatheters, and re-entry devices, and the companies supplying that ecosystem are worth tracking alongside the clinical literature.

Abbott Laboratories funded ORBITA-CTO through an Abbott Vascular research grant and supplies guidewires and stent platforms used across CTO practice.

Boston Scientific markets CTO-specific wires and support catheters and was among the disclosed institutional funders for the trial's senior editorialist.

Medtronic also supplies coronary guidewire and microcatheter systems relevant to complex CTO crossing strategies.

Teleflex, through its interventional franchise, supplies coronary support catheters used in retrograde and antegrade CTO techniques.

Company (Ticker)	CTO/Coronary Relevance	Analyst Consensus	Avg. Price Target	Market Cap Tier
Abbott Laboratories (ABT)	Guidewires, DES platforms; trial funder	Buy	$116.72	Large cap (~$170B+)
Boston Scientific (BSX)	CTO wires, microcatheters, coronary support	Strong Buy	$74.55	Large cap (~$65B+)
Medtronic (MDT)	Coronary guidewires, microcatheters	Buy	$97.77	Large cap (~$100B+)
Teleflex (TFX)	Interventional support catheters	Hold	$145.89	Mid cap (~$6B)

Prices, ratings, and targets sourced from StockAnalysis.com as of early July 2026; consensus figures compiled from S&P Global Market Intelligence and TipRanks and are subject to change.

Antianginal Drug Costs Relevant to the Trial Protocol

Because ORBITA-CTO withdrew and then reintroduced antianginal therapy, it is worth noting the out-of-pocket cost landscape for commonly used agents in this drug class.

Drug (Generic / Brand)	Typical Regimen	Approx. Cash Price (GoodRx, 60-tab supply)
Ranolazine / Ranexa	500 mg twice daily	~$21–29 generic with coupon; ~$220–280 brand cash price

No CTO-specific device carries a consumer-facing retail price in the way a prescription drug does, since guidewires, microcatheters, and re-entry systems are billed at the institutional and procedural level rather than itemized to patients.

Figure 2. Schematic placement of ORBITA-CTO within the evolving evidence base for CTO revascularization.

Physician education disclaimer: This article summarizes published trial data and congress reporting for clinician education and does not constitute individualized treatment guidance; revascularization decisions should follow shared decision-making, heart-team evaluation, and current society guidelines.

Financial disclaimer: Stock and pricing information is provided for general educational context only, is not investment advice, and may change after publication; consult a licensed financial advisor before making investment decisions. Drug pricing is approximate, cash-price based, and varies by pharmacy, region, and insurance coverage.

References

1. Khan S, Sajjad U, Fawaz S, et al. Randomized, placebo-controlled trial of chronic total occlusion percutaneous coronary intervention in stable angina: the ORBITA-CTO trial. JACC. 2026;88(1):4-18.
2. Ali ZA. ORBITA-CTO opens the door. JACC. 2026;88(1):22-23.
3. O'Riordan M. ORBITA-CTO: PCI reduces angina symptoms in sham-controlled trial. TCTMD, March 29, 2026.
4. Mahadevan K. A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina — ORBITA-CTO trial. PCRonline, April 3, 2026.
5. SCAI. ORBITA-CTO: a randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina — coverage of ACC 2026.
6. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31-40.
7. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. J Am Coll Cardiol. 2022;79:e21-e129.

Preventive Cardiology · Physician Briefing

The Convergence Era: CKM Syndrome, Fat Radiomics, and Wearables Reshape Cardiovascular Prevention

A new multisociety guideline, an AI-derived fat signature, and opportunistic imaging are quietly converging into a single question for every clinic visit: how early can risk be seen before disease is felt.

Preventive & Metabolic Cardiology Cardiac Imaging Digital Health Physician-Investor Briefing

01 · A Syndrome Gets a Name and a Playbook

Cardiovascular, kidney, and metabolic disease have always traveled together in the same patients.

The first comprehensive CKM syndrome guideline from the AHA and ACC, developed with the American Diabetes Association and American Society of Nephrology, formally retires the old obesity-only framework.

The guideline frames cardiovascular-kidney-metabolic (CKM) syndrome as a single interconnected condition rather than three separate referrals.

A five-tier staging system anchors the document, running from stage 0 (no risk factors) to stage 4 (established cardiovascular disease).

Stage 3 is the pivotal inflection point, capturing subclinical disease or a predicted ten-year risk of 20% or higher by the PREVENT risk equations.

Roughly 90 to 95 percent of American adults now fall somewhere on this stage 1-to-4 continuum, according to the guideline writers.

That statistic alone reframes CKM syndrome as a population-level default rather than a niche diagnosis.

The document gives a class 1 recommendation to interdisciplinary, team-based care anchored by a designated CKM coordinator for patients in stages 2 through 4.

Pharmacologic strategy leans on three overlapping tools: GLP-1 receptor agonists, SGLT2 inhibitors, and the nonsteroidal mineralocorticoid receptor antagonist finerenone, marketed as Kerendia by Bayer AG.

An accompanying editorial notes that obesity, diabetes, kidney disease, heart failure, and atherosclerotic disease are manifestations of one interconnected pathophysiology rather than isolated diagnoses.

Figure 1. The CKM staging framework positions stage 3 — subclinical disease — as the highest-value window for imaging-based detection.

02 · Fat as a Signal, Not Just a Risk Factor

Long before a guideline can stage a patient, imaging has to find the signal.

A large multicenter study applied automated radiomic phenotyping of epicardial adipose tissue to routine coronary CT angiography scans from more than 72,000 adults without known heart failure.

Epicardial fat is not inert padding around the heart; it is a metabolically active depot that both senses and modulates myocardial biology through paracrine signaling.

Investigators extracted over 1,600 volumetric, shape, and texture features from this fat depot using a fully automated pipeline.

A survival autoencoder model condensed these features into a single fat radiomic profile for heart failure, developed in one cohort and externally validated in a second, geographically distinct cohort.

The signature predicted incident heart failure independent of age, sex, coronary artery disease severity, and epicardial fat volume alone.

Because the underlying scan is already a routine coronary CT, the technique requires no additional radiation, contrast, or patient time.

This positions opportunistic, AI-derived fat analysis as a plausible bridge between a scan ordered for chest pain and a heart failure prevention conversation that would otherwise wait for symptoms.

03 · Coronary Calcium Finds Patients Who Never Asked to Be Scanned

A parallel body of work is chasing the same goal through a more familiar test: the coronary artery calcium (CAC) score.

AI-driven CAC detection on noncardiac CT scans extends calcium scoring to studies never intended for cardiovascular purposes, including lung cancer screening CTs.

This matters because roughly nine million American adults undergo lung cancer screening CT each year, almost none of which are read for cardiac risk.

Traditional ECG-gated CAC scans remain gold standard, but access is uneven and the test is not reliably covered by insurance.

That access gap has been shown to track with socioeconomic and health care disparities, meaning the patients least likely to get a dedicated CAC scan are often those who would benefit most from knowing their number.

Convolutional neural network and U-Net-based models can now extract calcium scores from these already-acquired scans with accuracy approaching dedicated gated studies.

For a physician-investor audience, this is the quiet argument for AI-enabled radiology software as a category, not a single-company bet.

04 · Wearables Move From Rhythm to Ischemia

The third convergence point is on the patient's wrist rather than in the scanner.

Consumer smartwatch electrocardiograms have historically excelled at one thing: flagging atrial fibrillation.

Newer work is testing whether the same hardware, paired with AI-enhanced multi-lead reconstruction, can flag acute coronary syndrome rather than just arrhythmia.

One study applied an AI algorithm trained on standard twelve-lead ECGs to a nine-lead configuration derived from sequential single-lead smartwatch recordings.

Early results suggest meaningful sensitivity and specificity for ischemic change detection, though the authors are careful to frame this as preliminary rather than clinic-ready.

The clinical logic is straightforward: a shortage of specialists to interpret conventional ECGs is a bottleneck that automated interpretation could partially relieve, particularly where access to a standard ECG machine is limited.

None of this replaces a 12-lead ECG or serial troponins in a patient with chest pain, and current guidance still centers on that standard pathway.

What it does offer is a plausible first alert in settings where that pathway is hours away.

Figure 2. Cardiac imaging, opportunistic AI-read calcium scoring, and wearable ECG triage are separate technologies converging on the same clinical target: subclinical disease before it declares itself.

Case Vignette

A 54-year-old warehouse manager with a body mass index of 33, borderline glucose intolerance, and treated hypertension undergoes a low-dose chest CT for lung cancer screening after a 30-pack-year smoking history.

The radiology report is negative for malignancy and, under an AI-assisted opportunistic screening protocol, flags a coronary artery calcium score in the moderate range.

Applying the CKM staging framework, this patient moves from stage 2 to stage 3 on the strength of that single incidental finding.

The case illustrates why opportunistic AI-read CAC, fat radiomics, and structured CKM staging are not competing tools but complementary checkpoints for the same category of patient: metabolically at-risk, asymptomatic, and easy to miss without a systematic prompt.

05 · Where the Capital Is Flowing

For physicians who also track the investable side of prevention, three categories are worth watching: metabolic pharmacotherapy, nonsteroidal MRA therapy, and AI-enabled cardiac imaging software.

Metabolic pharmacotherapy is dominated by two companies whose GLP-1 franchises are now explicitly named in guideline-level management pathways.

Table 1. Selected publicly traded companies relevant to CKM-era prevention

Company	Ticker	Relevant Product(s)	Analyst Consensus
Bayer AG	BAYRY (OTC ADR)	Finerenone (Kerendia) — nonsteroidal MRA for CKD and HF	Buy consensus; average 12-month target near $14
Novo Nordisk A/S	NVO (NYSE ADR)	Semaglutide (Ozempic, Wegovy) — GLP-1 receptor agonist	Buy consensus; average 12-month target near $48
Eli Lilly and Company	LLY (NYSE)	Tirzepatide (Mounjaro, Zepbound) — dual GIP/GLP-1 agonist	Buy/Strong Buy consensus; average 12-month target above $1,200
Cleerly, Inc.	No live ticker — privately held, pre-IPO	AI-based coronary CT plaque and calcium analysis software	Not applicable; private financing rounds only

The pricing gap in the CKM toolkit is stark and worth naming plainly for patient counseling: a 30-tablet supply of 10 mg Kerendia retails near $890 to $908 without insurance, discounted to roughly $640 to $695 with a GoodRx coupon.

No generic finerenone exists yet, with patent protection expected at minimum into 2029.

Bayer's manufacturer copay program can reduce eligible commercially insured patients' out-of-pocket cost to as little as zero dollars per month, capped at $3,000 in annual savings.

Table 2. Three prevention technologies at a glance

Technology	Signal Detected	Added Test Burden	Maturity
Epicardial fat radiomics on CCTA	Future heart failure risk	None — reuses existing scan	Externally validated, not yet commercial
AI-read opportunistic CAC	Subclinical atherosclerosis	None — reuses noncardiac chest CT	Multiple validated algorithms; early clinical rollout
Smartwatch AI-ECG for ACS	Acute ischemic change	Minimal — patient-owned device	Early-stage, preliminary accuracy data only

Bottom Line

The 2026 CKM guideline gives clinicians a shared staging language for a condition that already affects nearly all American adults in some degree.

Epicardial fat radiomics and AI-read opportunistic calcium scoring both extract new prognostic value from scans patients are already getting for other reasons.

Wearable AI-ECG for ischemia detection remains promising but preliminary, and should not yet substitute for standard troponin-and-ECG pathways.

Across all three, the unifying opportunity is the same: catching stage 3 disease before it becomes stage 4.

Physician education disclaimer: This article is intended for healthcare professional education and does not constitute clinical practice guidance for any individual patient; treatment decisions should follow current guideline recommendations and individualized clinical judgment.

Financial disclaimer: Stock tickers, analyst consensus ratings, and pricing figures are provided for general informational and educational purposes only, reflect data available at the time of writing, and do not constitute investment advice; consult a licensed financial advisor before making investment decisions.

References

1. American Heart Association / American College of Cardiology. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome — coverage via TCTMD.
2. American Heart Association Professional Heart Daily. Guideline summary and staging framework for CKM syndrome.
3. Early prediction of heart failure from routine cardiac CT using radiomic phenotyping of epicardial fat — PubMed abstract.
4. Artificial intelligence-driven advances in coronary calcium scoring: expanding preventive cardiology — PubMed Central.
5. Smartwatch ECG and artificial intelligence in detecting acute coronary syndrome compared to traditional 12-lead ECG — PubMed Central.
6. GoodRx. Kerendia (finerenone) pricing and patient assistance information.
7. StockAnalysis.com. Bayer Aktiengesellschaft (BAYRY), Novo Nordisk A/S (NVO), and Eli Lilly and Company (LLY) stock overviews and analyst forecasts.

Structural Heart • AI Diagnostics • Market Watch

AI-Enabled ECG Screening Finds the Structural Heart Disease Echo Would Have Missed

A composite AI-ECG signal predicted new structural disease years before it appeared — and the technology behind it may soon trade on a public exchange.

Structural heart disease (SHD) remains one of cardiology's most common blind spots.

Valvular disease, left ventricular hypertrophy, reduced ejection fraction, and pulmonary hypertension frequently go undetected until a patient presents with overt heart failure.

The reference standard, echocardiography, is accurate but constrained by cost, sonographer availability, and specialist interpretation.

New multinational data presented at New York Valves 2026 suggest that a simple 12-lead ECG, read by an artificial intelligence (AI) algorithm, can flag patients who need that echo before disease progresses.

Composite-positive patients were up to 3.75 times more likely to develop new SHD over six years than composite-negative patients.

Case Vignette

A 61-year-old with well-controlled hypertension presents for an annual physical with no cardiac complaints.

A routine 12-lead ECG obtained for the visit is run through an AI-ECG structural heart disease algorithm and returns a composite-positive result.

The patient has no murmur, normal oxygen saturation, and an unremarkable physical exam.

Guided by the AI-ECG flag rather than symptoms, the primary care physician refers for transthoracic echocardiography, which reveals moderate aortic stenosis with preserved ejection fraction.

Without the AI-ECG signal, this asymptomatic valvular disease likely would not have been captured for years.

Why Structural Heart Disease Slips Through

SHD is a leading contributor to heart failure and cardiovascular death, yet it is frequently silent in its early stages.

Echocardiography remains definitive, but its cost and the need for trained sonographers and interpreting physicians limit how broadly it can be deployed as a screening tool.

ECGs, by contrast, are inexpensive, ubiquitous, and already collected during routine care in primary care offices, emergency departments, and even on consumer wearables.

The clinical opportunity is to use the ECG's existing signal, amplified by AI, to decide who actually needs the more expensive test.

A related approach from Columbia University Irving Medical Center's EchoNext model found that nearly half of high-risk patients would not have received an echocardiogram under routine care alone.

The Composite AI-ECG Signal

The model discussed at New York Valves 2026 combines two previously validated algorithms.

One component, trained to detect left ventricular systolic dysfunction (ejection fraction below 40%), correlates most strongly with reduced pump function.

The second component, trained to detect left ventricular diastolic dysfunction (septal E/e' above 15), correlates more broadly with valvular disease, hypertrophy, and pulmonary hypertension.

Combining the two into a single composite-positive/negative output was designed to capture the fuller spectrum of SHD rather than any single subtype.

Both underlying algorithms already carry regulatory clearance and are in clinical use in South Korea.

What the Multinational Data Showed

Investigators pooled retrospective data from three cohorts: a South Korean hospital network, an academic center in New York, and the UK Biobank.

SHD prevalence differed sharply by cohort, ranging from roughly one in eight patients to more than four in ten, reflecting differences in referral patterns and population risk.

Despite that variation, the composite AI-ECG score performed consistently across all three groups.

Cohort	Sample Size	SHD Prevalence	Composite Sensitivity
Incheon Sejong Hospital (South Korea)	46,082	12.7%	71.8%
Columbia University Irving Medical Center (New York)	36,286	43.6%	76.1%
UK Biobank	41,226	Not separately reported	Consistent with above

Beyond detecting prevalent disease, the score also predicted incident SHD over six years of follow-up.

Composite-positive patients had a 3.75-fold greater risk of developing new SHD in the South Korean cohort and a 2.75-fold greater risk in the UK Biobank, compared with composite-negative patients.

Outcome Comparison	Composite-Positive vs. Negative
Incident SHD risk, South Korean cohort (6-yr)	3.75-fold higher
Incident SHD risk, UK Biobank (6-yr)	2.75-fold higher
Prior heart-failure risk data (separate US cohorts)	~20-fold higher; outperformed the AHA PREVENT-HF equation

Figure 1. Proposed clinical workflow: a single ECG feeds a composite AI algorithm, which triages patients toward or away from confirmatory echocardiography.

Figure 2. Relative risk of incident structural heart disease or heart failure in composite AI-ECG-positive vs. -negative patients across studies.

The Implementation Debate

A discussant at the meeting noted that the vast majority of ECGs recorded in daily practice are never systematically acted upon.

AI, in his framing, is not a diagnostic leap so much as an efficient way to extract signal that was already sitting in a waveform physicians routinely order anyway.

He cautioned that the models still leave room for missed cases, meaning a negative AI-ECG result should not override clinical suspicion.

He also raised an unresolved medicolegal question that will matter to any cardiologist adopting this technology: liability when a model's judgment differs from a physician's, in either direction.

Both the presenting investigator and the discussant agreed that prospective trials, not retrospective analyses, are needed before broad workflow integration, and randomized trials are reportedly being planned in the US and South Korea.

The Investor Angle: Who Makes These Algorithms

The composite algorithm in this study, marketed as AiTiALVSD and AiTiALVDD, is developed by Medical AI Co.PRIVATE / PRE-IPO

Medical AI is a South Korean company spun out of Sejong Hospital that has publicly stated it is preparing for a technology-specific listing on the KOSDAQ exchange after receiving top ratings from Korea Exchange evaluators.

As of this writing, the company has no public ticker, so investors cannot yet buy shares directly; readers should treat any pre-IPO valuation chatter with appropriate skepticism.

For physician-investors tracking the broader Korean medical-AI sector, two already-listed comparators illustrate how these business models have performed once public, though neither is an ECG-specific competitor.

Company	Ticker	Focus Area	Notes
Medical AI Co.	Private	AI-ECG for LV systolic/diastolic dysfunction	Preparing for KOSDAQ listing; maker of the algorithm in this study
Lunit Inc.	KOSDAQ: 328130	AI for oncology imaging and pathology	Publicly traded Korean medical-AI peer; not an ECG company
Vuno Inc.	KOSDAQ: 338220	AI for imaging (chest X-ray, bone age, fundus)	Publicly traded Korean medical-AI peer; not an ECG company

What This Could Mean for Echo Volumes and Reimbursement

Every AI-ECG-driven referral for confirmatory imaging is, from a health-system standpoint, an additional transthoracic echocardiogram (CPT 93306).

Medicare's national average reimbursement for a complete echocardiogram with Doppler runs roughly $210 to $260 globally, split between technical and professional components, while commercially negotiated and self-pay prices vary far more widely across hospitals.

If AI-ECG screening is adopted broadly, echo labs and cardiology groups performing in-house imaging could see meaningful volume growth, an operational detail worth factoring into staffing and capital equipment planning.

Conversely, payers may eventually push back on expanded echo utilization driven by an unvalidated screening trigger, which is one reason prospective outcomes data will matter for coverage policy as much as for clinical guidelines.

Bottom Line

A composite AI-ECG score detected prevalent structural heart disease with roughly 72% to 76% sensitivity across three international cohorts.

The same score predicted new-onset disease years in advance, with composite-positive patients carrying up to nearly four-fold higher risk.

The tool is already regulatory-cleared and deployed in South Korea, but remains retrospectively validated, and prospective randomized trials are still pending before this becomes standard US workflow.

The company behind the algorithm is privately held and preparing for a stock exchange listing, so there is currently no way to invest in it directly; broader Korean medical-AI names offer indirect sector exposure but are not therapeutic equivalents.

Physician education disclaimer: This article is intended for healthcare professional education and does not constitute individualized clinical guidance; treatment and screening decisions should be individualized and based on current guidelines and full clinical context.

Financial disclaimer: This article is for general informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security; all company, valuation, and reimbursement figures are subject to change, and readers should consult a licensed financial advisor before making investment decisions.

References

1. AI-ECG Models Detect Structural Heart Disease, Identify At-Risk Patients. TCTMD, presented at New York Valves 2026.
2. AI for Heart Failure Care Is Evolving Rapidly, THT 2026 Makes Clear. TCTMD.
3. Predicting Risk of Cardiovascular Disease Events (PREVENT) Calculator. American Heart Association, Professional Heart Daily.
4. Variation in Cost of Echocardiography Within and Across US Hospitals. PMC.
5. Medical AI Co. — Company Overview. Medical AI corporate site.
6. Lunit Inc. (KOSDAQ: 328130) Stock Overview. StockAnalysis.com.
7. Vuno Inc. (KOSDAQ: 338220) Stock Overview. StockAnalysis.com.

Oxygen After Cardiac Arrest: The LOGICAL Trial Closes the Book on "Less Is More"

A large multinational RCT finds no functional or survival benefit to conservative oxygen titration in unresponsive post-arrest ICU patients.

For more than a decade, a plausible biological story has driven ICU oxygen practice after cardiac arrest.

Animal data suggested that hyperoxemia during the reperfusion window worsens oxidative brain injury, and several small trials hinted that a conservative oxygen strategy might improve neurologic recovery.

The LOGICAL trial, published this June in the New England Journal of Medicine, was designed to settle the question definitively.

The answer, in short, is that it did not settle in favor of the conservative strategy at all.

What LOGICAL Actually Tested

Investigators enrolled 1,840 unresponsive adults from 53 ICUs across Australia, New Zealand, and Ireland who were undergoing mechanical ventilation after return of spontaneous circulation (ROSC).

Most arrests were out-of-hospital and witnessed, and roughly three in four patients received bystander CPR.

Median time from ROSC to randomization was about seven hours, which is notably longer than in several prior oxygen trials.

Patients were randomized to either a conservative oxygen protocol or a liberal oxygen protocol, with both sharing a default lower SpO2 alarm limit of 90%.

Figure 1. Protocol design of the two randomized oxygen strategies in LOGICAL.

The Primary Result: Convincingly Neutral

At 180 days, a favorable functional outcome occurred in 38.2% of the conservative-oxygen group versus 39.7% of the liberal-oxygen group, a difference that was not statistically significant.

Survival to day 180 was likewise similar between arms, at 48.0% with conservative oxygen and 49.7% with liberal oxygen.

Quality-of-life scores, patient- or proxy-reported health state, and cognitive testing via the Montreal Cognitive Assessment showed no meaningful separation between groups.

Prespecified subgroup analyses, including stratification by time from ROSC to randomization, showed no signal favoring either strategy.

The trial's own investigators described the findings as consistent regardless of when oxygen titration began.

Figure 2. Approximate rates of favorable functional outcome (or comparable neurologic endpoint) across three contemporary oxygen-titration trials in post-arrest patients; values are approximate and trial endpoints/definitions differ, so cross-trial comparison is illustrative rather than statistical.

How LOGICAL Fits With the Rest of the Evidence

LOGICAL is nested within the much larger Mega-ROX program, which will eventually add roughly 2,200 more patients and report in-hospital mortality as its primary endpoint.

The trial's findings align closely with the earlier BOX trial, which also found no difference between restrictive and liberal oxygen targets in comatose out-of-hospital arrest survivors.

They likewise mirror the prehospital EXACT trial, which found no neurologic benefit from a conservative approach and raised concern about titration accuracy in the field.

Together, these three modern, adequately powered trials stand in contrast to an earlier generation of smaller studies, including ICU-ROX, that had suggested a possible mortality benefit with conservative oxygen.

A prior individual patient-level meta-analysis had found a statistically significant mortality reduction with conservative oxygen, but the certainty of that evidence was rated low given bias and imprecision across small trials.

Table 1. Contemporary randomized trials of oxygen strategy after cardiac arrest

Trial	Population	Comparison	Primary Result
LOGICAL (2026)	Unresponsive ICU patients post-arrest, in/out-of-hospital	Conservative vs liberal FiO2/SpO2	No difference in 180-day favorable outcome
BOX	Comatose OHCA survivors	Restrictive vs liberal oxygen target	No difference in mortality/neurologic outcome
EXACT	Prehospital OHCA patients	Conservative vs usual-care oxygen titration	No neurologic benefit; titration challenges noted
ICU-ROX (earlier era)	ICU patients with suspected HIE post-arrest	Conservative vs usual oxygen	Lower day-180 mortality with conservative oxygen (smaller trial)

Practical Implications for the ICU

The most defensible reading of this body of evidence is that hitting a specific low oxygen target does not, by itself, rescue the injured brain after arrest.

An SpO2 floor around 90% to avoid frank hypoxemia remains reasonable, since both LOGICAL arms shared that lower limit.

Chasing an aggressively low ceiling with tight alarms, however, does not appear to add measurable neurologic or survival benefit and adds nursing and respiratory therapy titration burden.

Clinicians should also note that neuroprognostication protocols and their timing did not differ meaningfully between groups, so the neutral result is unlikely to reflect an assessment artifact.

Because LOGICAL enrolled from high-income health systems in Australia, New Zealand, and Ireland, generalizability to resource-limited ICUs remains uncertain pending the broader Mega-ROX HIE dataset.

Table 2. LOGICAL protocol parameters at a glance

Parameter	Conservative Group	Liberal Group
Default lower SpO2 alarm	90%	90%
Upper SpO2 alarm	95%	Not set
Minimum FiO2 during ventilation	0.21 (once SpO2>90%)	0.30
Procedural high-FiO2 exceptions	Permitted	Permitted
180-day favorable functional outcome	38.2%	39.7%
180-day survival	48.0%	49.7%

Case Vignette

A 58-year-old is brought to the ICU after an out-of-hospital arrest with bystander CPR and return of circulation after 22 minutes.

The patient remains unresponsive on mechanical ventilation six hours after ROSC, and the team is deciding on an oxygenation target while awaiting further neuroprognostic testing.

Based on LOGICAL, the team can reasonably set a standard lower SpO2 alarm around 90% without feeling obligated to enforce an aggressively low FiO2 ceiling.

The decision can instead focus on avoiding both hypoxemia and extreme hyperoxemia using routine ICU oxygen management, rather than a rigid conservative protocol.

Bottom Line

In the largest trial of its kind, a conservative oxygen strategy did not improve 180-day survival, functional outcome, quality of life, or cognition compared with a liberal strategy in unresponsive post-arrest ICU patients.

These results are consistent with BOX and EXACT, reinforcing that meticulous low-oxygen titration protocols are unlikely to be the lever that improves outcomes after cardiac arrest.

The larger Mega-ROX HIE program, expected to add roughly 2,200 additional patients with an in-hospital mortality endpoint, is anticipated to be confirmatory rather than to reverse this signal.

Routine, pragmatic oxygen management with a reasonable lower SpO2 threshold remains a sound default pending further data.

This article is intended for physician education and reflects a summary of publicly available trial data; it is not a substitute for independent review of the primary literature or institutional protocols before changing clinical practice.

References

1. Conservative Oxygen for Unresponsive Patients after Cardiac Arrest — New England Journal of Medicine
2. LOGICAL: Conservative Oxygen Therapy Fails to Improve Survival Outcomes After Cardiac Arrest — ACC.org Journal Scan
3. LOGICAL Trial Overview — Australian and New Zealand Intensive Care Society
4. Protocol Summary and Statistical Analysis Plan for the LOGICAL Trial — PMC
5. Higher BP, Oxygen Targets No Help in Comatose OHCA Patients: BOX — TCTMD

Physician Education · Interventional & Preventive Cardiology

The 2026 ACC Antiplatelet Statement: A Field Guide to Balancing Ischemia and Bleeding

What changed, what stayed the same, and what it costs — a high-yield synthesis for the practicing cardiologist.

The 2026 ACC Scientific Statement on antiplatelet therapy pulls together a decade of fragmented guidance into one document spanning primary prevention, acute coronary syndrome (ACS), peripheral artery disease (PAD), stroke, valve disease, and perioperative care.

Its central theme is not a single new drug but a philosophy: match antiplatelet intensity to a patient's ischemic risk trajectory, then de-escalate as that risk falls and bleeding risk does not.

Below is the condensed, point-of-care version.

Primary Prevention: Aspirin's Shrinking Lane

Aspirin remains the cheapest and most widely used antiplatelet available, but the statement is blunt about its limits in primary prevention.

A pooled meta-analysis of 13 trials and over 165,000 participants found a modest 11% relative reduction in cardiovascular events (HR 0.89) but a 43% relative increase in major bleeding.

The number needed to treat to prevent one event was 241, against a number needed to harm of 880 for intracranial hemorrhage specifically.

The statement's practical rule: consider low-dose aspirin only in adults aged 40–70 with elevated ischemic risk and low bleeding risk, and avoid routine use after age 70.

Coronary artery calcium scoring helps sharpen that decision, with scores ≥100–400 identifying patients most likely to see net benefit.

Aspirin for Primary Prevention — Benefit vs. Harm (per 1,000 patient-years)

Choosing and Timing DAPT After ACS or PCI

For patients with ACS undergoing percutaneous coronary intervention (PCI), the statement favors prasugrel or ticagrelor over clopidogrel as the default P2Y12 inhibitor, based on the PLATO and TRITON-TIMI 38 trials.

Clopidogrel is preferred instead in patients over 75, given a higher bleeding risk with the more potent agents in that age group.

Default dual antiplatelet therapy (DAPT) duration is 12 months for ACS and 6 months for chronic coronary disease, with aspirin continued throughout the peri-PCI period.

A cluster of trials — TWILIGHT, TICO, and T-PASS — showed that dropping aspirin after 1–3 months and continuing the P2Y12 inhibitor alone cuts bleeding without a rise in ischemic events, but this evidence base applies mainly to ticagrelor, not clopidogrel.

Unguided de-escalation from ticagrelor or prasugrel down to clopidogrel at 1 month is a reasonable option in selected lower-risk patients who prioritize bleeding reduction.

Setting	Default DAPT Duration	Early De-escalation Option
ACS + PCI	12 months (aspirin + prasugrel/ticagrelor)	P2Y12 monotherapy at 1–3 mo (ticagrelor best supported)
Chronic coronary disease + PCI	6 months (aspirin + clopidogrel)	P2Y12 monotherapy at 1–3 mo in selected patients
PAD, post-revascularization	1–6 months	Single antiplatelet + low-dose rivaroxaban long term
Minor stroke / high-risk TIA	21 days (aspirin + clopidogrel)	Antiplatelet monotherapy thereafter
CABG	Aspirin monotherapy is standard	DAPT lowers vein-graft failure only, at a bleeding cost

Case Vignette

A 68-year-old with a non-ST-elevation MI undergoes PCI with a drug-eluting stent and is discharged on aspirin plus ticagrelor.

At the 1-month visit she reports easy bruising and asks whether she really needs two blood thinners for a full year.

Using the statement's framework, her interventional cardiologist checks her ARC-HBR criteria, finds none met, and offers a evidence-based option: continue ticagrelor and drop aspirin now, per the TWILIGHT and TICO data, since her ischemic risk has already fallen substantially past the first month.

Long-Term Therapy Beyond One Year

Past the first year after ACS, the statement highlights emerging data that clopidogrel monotherapy may outperform aspirin monotherapy for secondary prevention, with similar or lower bleeding, based on HOST-EXAM 10-year follow-up and SMART-CHOICE 3.

For very high-risk patients with stable coronary or peripheral artery disease, adding low-dose rivaroxaban 2.5 mg twice daily to aspirin 81 mg daily is a reasonable long-term option, based on the COMPASS trial's reduction in MACE and total mortality.

This "vascular dose" strategy is not appropriate for anyone with a prior stroke or major bleeding history.

Special Populations in Brief

In PAD, shorter DAPT courses (1–6 months) are typical after revascularization, and low-dose rivaroxaban added to aspirin reduces both major cardiac and major limb events per VOYAGER-PAD.

In minor ischemic stroke or high-risk TIA, DAPT with aspirin and clopidogrel for 21 days beats aspirin alone for reducing recurrent stroke, after which therapy steps back down to monotherapy.

Triple therapy combining an anticoagulant with dual antiplatelets should be avoided; the default after PCI in a patient needing oral anticoagulation is a short aspirin run-in followed by an anticoagulant plus clopidogrel.

Patients with a bioprosthetic aortic or mitral valve typically do fine on single antiplatelet therapy (low-dose aspirin) long term, with no added benefit from routine DAPT or anticoagulation.

Ischemic vs. Bleeding Risk Over Time After an Acute Event

Monitoring, Interactions, and Adherence

CYP2C19 loss-of-function alleles reduce clopidogrel's active metabolite and raise thrombotic risk after PCI, though routine genotyping remains optional rather than mandated.

Concomitant omeprazole theoretically blunts clopidogrel's antiplatelet effect via shared CYP2C19 metabolism, but randomized data show no increase in ischemic events, so proton pump inhibitors are still recommended in patients at high bleeding risk.

Cost is a major driver of nonadherence: roughly one in four low-income families with ASCVD faces significant financial burden from medication costs, and early discontinuation of DAPT after MI raises the risk of stent thrombosis.

Generic clopidogrel is the cheapest option, generic ticagrelor and prasugrel are now increasingly available, and dose reduction of ticagrelor to 60 mg twice daily after the acute phase cuts nonadherence driven by bleeding and dyspnea without losing efficacy.

Drug and Device Reference Table

Agent	Class	Approx. Monthly Cost (generic, GoodRx)	Maker (Ticker)
Clopidogrel (Plavix)	P2Y12 inhibitor	$5–$10	Originator Sanofi SNY
Ticagrelor (Brilinta)	P2Y12 inhibitor	$23–$35 (generic); brand ~$460+	AstraZeneca AZN
Prasugrel (Effient)	P2Y12 inhibitor	$14–$20	Daiichi Sankyo / Eli Lilly LLY
Rivaroxaban 2.5 mg (Xarelto)	Factor Xa inhibitor, "vascular dose"	~$37–$45 (generic 2.5 mg)	Johnson & Johnson/Janssen JNJ; co-marketed by Bayer
Aspirin, low dose	COX-1 inhibitor	Under $5	Multiple generic manufacturers

Bottom Line

Antiplatelet strategy in 2026 is a moving target that shifts with time-since-event, not a fixed prescription written at discharge.

Start intensively when ischemic risk is highest, reassess bleeding risk at every visit using tools like ARC-HBR, and be willing to de-escalate once the first month or two has passed — especially with ticagrelor, where the evidence for early aspirin withdrawal is strongest.

Cost and adherence deserve the same attention as pharmacology, since a cheaper regimen a patient actually takes beats an optimal one they abandon.

References

1. American College of Cardiology. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement. J Am Coll Cardiol. 2026.
2. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI (TWILIGHT). N Engl J Med. 2019;381:2032-2042.
3. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS). N Engl J Med. 2017;377:1319-1330.
4. Kang J, Park S, Yang H-M, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after PCI: 10-year follow-up of HOST-EXAM. Lancet. 2026;407:1439-1447.
5. Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321:277-287.

Clinical disclaimer: This article summarizes a scientific statement for physician education and is not a substitute for individualized clinical judgment or the full guideline text. Financial disclaimer: Ticker and pricing information is for general reference only, is not investment advice, and changes frequently; consult a licensed financial advisor and current pharmacy sources before making decisions.